37 studies found for:    SLC2A2
Show Display Options
Rank Status Study
1 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Conditions: Diabetes Mellitus, Type 2;   Renal Insufficiency
Interventions: Drug: Canagliflozin;   Drug: Placebo
2 Completed A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: JNJ-28431754/ Placebo;   Drug: JNJ-28431754
3 Recruiting Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Conditions: Diabetes Mellitus, Type 2;   Hypertension
Interventions: Drug: Canagliflozin;   Drug: Placebo
4 Completed SLC2A1 Variants and Diabetic Nephropathy
Condition: Diabetic Nephropathy.
5 Recruiting Common Variation at SLC16A11 and Other Genes on the Response to a Mixed Meal Tolerance Test
Conditions: Genetics;   Metabolism;   Type 2 Diabetes
Interventions: Other: Mixed Meal Tolerance Test;   Drug: Metformin
6 Not yet recruiting The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome
Conditions: Schizophrenia;   Metabolic Syndrome
7 Completed Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)
Conditions: Attention Deficit Disorder With Hyperactivity;   Methylphenidate;   Pharmacogenetics
Intervention: Genetic: norepinephrine transporter polymorphism,
8 Unknown  Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871
Conditions: Bladder Cancer;   Breast Cancer;   Head and Neck Cancer;   Lung Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: docetaxel;   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Unknown  Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Methylphenidate
10 Enrolling by invitation Mobile Health Technology as an Intervention for Diabetes Self-Management
Condition: Type II Diabetes Mellitus
Intervention: Other: Participation in Care4Life
11 Completed Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Methylphenidate
12 Recruiting An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
13 Unknown  Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
Condition: Hearing Loss
Intervention: Drug: Proton pump inhibitor
14 Completed Predicting Medication Response in Obsessive Compulsive Disorder
Condition: Obsessive Compulsive Disorder
Interventions: Drug: clomipramine;   Drug: escitalopram;   Drug: duloxetine
15 Not yet recruiting Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
Condition: Solid Tumours
Intervention: Drug: SLC-0111
16 Unknown  Structural Connectivity as Imaging Endophenotypes of Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
17 Completed Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes
Condition: Diabetes
Intervention: Dietary Supplement: Zinc acetate
18 Recruiting TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib/Nilotinib
19 Completed
Has Results
A Study of Aripiprazole in Patients With Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Aripiprazole+ ADT;   Drug: Placebo+ ADT
20 Completed 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Condition: Alzheimer Disease
Intervention: Drug: xaliproden (SR57746A)

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Indicates status has not been verified in more than two years